阿司匹林抵抗的研究现状  

The Current Statement of Aspirin Resistance

作　　者：赵燕[1] 沈潞华[2] 杨明[1] 

机构地区：[1]首都医科大学附属复兴医院心内科,北京100038 [2]首都医科大学附属友谊医院,北京100000

出　　处：《心血管病学进展》2006年第6期744-747,共4页Advances in Cardiovascular Diseases

摘　　要：阿司匹林抵抗即阿司匹林不能减少血小板血栓素A2的生成并因此引起血小板活化和聚集。阿司匹林抵抗的可能原因包括用量不当、药物相互作用、环氧合酶-1的遗传多态性和涉及血栓素生物合成的其他基因、血栓素生物合成的非血小板源性因素的上调和血小板更新增强。阿司匹林抵抗程度的增强可能与心血管事件风险的增加独立相关。目前还没有一种精确定性和定量分析的方法来检测阿司匹林的抗血小板功能异常,从而解释生物化学的阿司匹林抵抗。今后的研究旨在准确定义阿司匹林抵抗、开发可靠的检测方法并确定相关心血管事件的发生风险。Aspirin resistance has been defined as failure of suppression of thromboxane generation and lead to platelet activated and aggregated. The reason for aspirin resistance may be the drug dose used incorrectly and COX-1 enzyme genetic polymorphism. Aspirin resistance may increase the risk of cardiovascular events. Aspirin resistance has been assessed by various laboratory methods that may be overestimated. We need to define aspirin resistance correctly and find specific laboratory measurements to determine the prevalence of platelet aspirin resistance.

关 键 词：阿司匹林抵抗 血栓素A2 尿11-脱氢血栓素B2 

分 类 号：R971.1[医药卫生—药品]